

FACULTY BIOGRAPHY



Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor, Medicine
Harvard Medical School
Boston, MA

Jeremy S. Abramson, MD, MMSc, is the director of the Lymphoma Program, the Jon and Jo Ann Hagler chair in lymphoma at the Massachusetts General Hospital Cancer Center, and an associate professor of medicine at Harvard Medical School in Boston, MA. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York, NY and a master's degree in medical sciences in clinical investigation from Harvard Medical School. He completed his residency in internal medicine at Massachusetts General Hospital, followed by a fellowship in hematology and oncology at the Dana-Farber Cancer Institute. Dr. Abramson is board certified in medical oncology.

Dr. Abramson's clinical and research interests are in non-Hodgkin lymphomas, Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL). His research involves the design and conduct of clinical trials of targeted therapies and immunotherapies in these diseases.

FACULTY BIOGRAPHY



Joshua Brody, MD

Director, Lymphoma Immunotherapy Program
Tisch Cancer Institute at Mount Sinai
Faculty, Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
Mount Sinai Hospital
New York, NY

Joshua Brody, MD, is the director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a faculty member of the Icahn Genomics Institute in New York, NY. Since joining Mount Sinai, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab that investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals, including *Nature Medicine* and *Cancer Discovery*. Dr. Brody is board certified in medical oncology.

Dr. Brody has pioneered a therapeutic vaccine approach – *in situ* vaccination – that induces anti-tumor immunity at the tumor site and can also cause regression of tumors throughout the body. He has also developed a way to increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation. Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.

Dr. Brody's research receives funding from numerous grantors, including the National Institutes of Health, the Cancer Research Institute, the Damon Runyon Cancer Research Foundation, and the Lymphoma Research Foundation. He is a member of many professional organizations, including the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology.